Objective Emerging pathological evidence suggests that there is an association between
glymphatic dysfunction and the progression of Parkinson's disease (PD). However, the …

Concomitant Alzheimer's disease (AD) pathology is a frequent event in the context of Lewy
body disease (LBD), occurring in approximately half of all cases. Evidence shows that LBD …

Cognitive impairment is a frequent manifestation of Parkinson's disease (PD), resulting in
decrease in patients' quality of life and increased societal and economic burden. However …

Background Parkinson's disease (PD) is associated with cognitive decline through multiple
mechanisms, including Alzheimer's disease (AD) pathology and cortical Lewy body …

Plasma Alzheimer's disease-related pathological biomarkers' role in Parkinson's disease
(PD) remains unknown. We aimed to determine whether plasma Alzheimer's disease …

Objective To assess the prevalence, evolution, clinical characteristics, correlates and
predictors of fatigue as well as to investigate the influence of comorbid fatigue on the …

Background Recent evidence suggests a link between glycoprotein non-metastatic
melanoma protein B (GPNMB) and Parkinson's disease (PD) pathogenesis. Although …

Pathologies characteristic of Alzheimer's disease (ie, hyperphosphorylated tau and amyloid-
β (Aβ) plaques), cardiovascular disease, and limbic predominant TDP-43 encephalopathy …

The progression of Parkinson's disease (PD) is often accompanied by cognitive decline. We
had previously developed a brain age estimation program utilizing structural MRI data of …

Parkinson's disease (PD) is a degenerative neurological disorder resulting from the death of
dopaminergic neurons, which, in turn, results in impaired motor and cognitive functions …